Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa trial of PVT-100 in patients with vulnerable plaque who are to undergo carotid endarterectomy

Next Previous
Trial Profile

Phase IIa trial of PVT-100 in patients with vulnerable plaque who are to undergo carotid endarterectomy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms POMEGA
  • Sponsors Pivotal Therapeutics

    • Most Recent Events

    • 04 Jun 2015 According to a Pivotal Therapeutics media release, the trial entitled "Impact of an optimized Omega 3 formulation on the biochemical and histopathological composition of atheromatous plaques in patients to undergo carotid endarectomy" is sponsored by the University Hospital of Strasbourg and coordinated by interdisciplinary team of six vascular surgeons and twenty health professionals and monitored by the French health authorities via the national Clinical Trial Management System (CTMS).
    • 04 Jun 2015 According to a Pivotal Therapeutics media release, the company has enrol its first patient in the trial.
    • 04 Jun 2015 Status changed from planning to recruiting according to a Pivotal Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top